CompaniesMethylGene

MethylGene

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (3)

Total Trials

3

As Lead Sponsor

1

As Collaborator

2

Total Enrollment

234

By Phase

PHASE1/PHASE2: 2PHASE2: 1

By Status

COMPLETED: 2TERMINATED: 1

Clinical Trials Pipeline3 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

Today

Hover over trial bars to see details

Recent Trials

NCT02429375Collaborator

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE1/PHASE2Completed

Started: Apr 22, 2015 · Completed: Feb 17, 2021

NCT02282358Collaborator

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PHASE1/PHASE2Terminated

Started: Oct 31, 2014 · Completed: May 26, 2023

NCT01497223Lead Sponsor

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

PHASE2Completed

220 participants

Started: Dec 31, 2011 · Completed: Apr 30, 2013

Funding History (4)

D

Nov 21, 2012

D/A

Nov 16, 2012

D/A

Sep 11, 2012

D

Apr 7, 2011